Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the advantages of using imaging information for prostate cancer diagnosis and management at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Walz explains that prostate cancer, according to EAU guidelines, is currently diagnosed by randomized biopsy without using imaging information to target the tumor. Several technologies are available to promote the use of imaging information in prostate cancer diagnosis. Reliable imaging will allow decisions to be made on whether a cancer needs to be treated or followed by active surveillance. He concludes that the use of imaging can result in effective treatment of a cancer which may be lethal or affect quality of life.